Understanding New FDA’s Guidance on Biosimilar Product Development
July 13, 2012
The Knowledge Congress
As part of The Knowledge Congress’ live webinar series, Finnegan partner Sanya Sukduang will join a panel discussion regarding the Food and Drug Administration’s first draft guidance on biosimilar products and implications of the guidance. The two-hour program is eligible for 1.75 - 2.0 CLE credits. For more information, or to register, please see The Knowledge Congress’ website.